A Phase 3 interventional study of Zovaglutide dose 1 and Zovaglutide dose 2 in Overweight , Obesity, sponsored by Beijing QL Biopharmaceutical Co.,Ltd. Active, not recruiting at 45 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Beijing QL Biopharmaceutical Co.,Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd — 2 open to participants now, 7 under way, 1 of them phase 3. Obesity · Beijing QL Biopharmaceutical Co.,Ltd.
Among the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, this one has the largest enrollment, is one of 6 that started in 2026, is the only one in phase 3, and was the 3rd registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →2 of the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd are open now, in 1 country. Recruiting first, the newest first:
Beijing QL Biopharmaceutical Co.,Ltd · Sites in China
Ages 18–75
Beijing QL Biopharmaceutical Co.,Ltd · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 755 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 77 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
6 of the studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07230119Phase 3Beijing QL Biopharmaceutical Co.,LtdA Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) | 2027-05-29 |
| NCT07443059Beijing QL Biopharmaceutical Co.,LtdA Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants | 2026-12-03 |
| NCT07550816Beijing QL Biopharmaceutical Co.,LtdDrug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | 2026-12-05 |
| NCT07230132Beijing QL Biopharmaceutical Co.,LtdEfficacy and Safety of ZT006 in Overweight and Obese Participants | 2026-12-12 |
| NCT07697846Beijing QL Biopharmaceutical Co.,LtdA Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults | 2027-01-13 |
Add all 6 to your calendar (.ics) → With an account.
Among the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 755 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
2.At screening and prior to randomization, must meet one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered subcutaneously (SC), Q4W
Drug: Zovaglutide dose 1
administered subcutaneously (SC), Q4W
Drug: Zovaglutide dose 2
Administered subcutaneously (SC), Q4W
Drug: Placebo
administered subcutaneously (SC), Q4W
Also known as: ZT002 Injection
administered subcutaneously (SC), Q4W
Also known as: ZT002 Injection
administered subcutaneously (SC), Q4W
Change in body weight(%)
Time frame: baseline (week 0) to week 52
Proportion of subjects achieving ≥ 5% weight loss
Time frame: 52 weeks
Proportion of subjects achieving ≥10% weight loss
Time frame: week 52
Proportion of subjects achieving ≥15% weight loss.
Time frame: week 52
Proportion of subjects achieving ≥20% weight loss.
Time frame: week 52
Change in body weight (kg)
Time frame: Baseline (week 0) to week 52
Change in BMI (kg/m²)
Time frame: Baseline (week 0) to week 52
Change in waist circumference (cm)
Time frame: Baseline (week 0) to week 52
Change in hip circumference (cm)
Time frame: Baseline (week 0) to week 52
Number of Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline (week 0) to week 56
Number of Serious Adverse Events (SAEs)
Time frame: Baseline (week 0) to week 56
Positive rate of anti-drug antibodies (ADA).
Time frame: Baseline (week 0) to week 56
Positive rate of neutralizing antibodies (Nab)
Time frame: Baseline (week 0) to week 56
Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 16 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZT002
Beijing QL Biopharmaceutical Co.,Ltd →